According to a small new study published Wednesday in JAMA Internal Medicine, hydroxychloroquine, once promoted by President Donald Trump as a COVID-19 treatment, did not show a clinical benefit to prevent infection with the virus. Hydroxychloroquine and chloroquine, a sister formulation, are approved in the US as a treatment for malaria, lupus, and rheumatoid arthritis. In the early days of coronovirus outbreaks in the US, the Food and Drug Administration granted the drug an emergency use authorization, which was subsequently tested in several clinical trials as a treatment and also for subsequent exposure and pre-exposure prophylaxis. it was done. (The EUA was subsequently repealed.) This randomized, placebo-controlled study evaluated an eight-week diet of hydroxychloroquine in 132 hospital-based health care workers in Pennsylvania, which exposed patients to COVID-19 Were in Researchers reported that giving hydroxychloroquine “did not reduce the incidence of SARS-COV-2 infection compared to placebo,” the researchers wrote. Several studies published this summer also found that hydroxychloroquine did not benefit COVID-19 patients or work to prevent infection.